Neuro

Epilepsy Foundation Elects New Board Members and Chair as the Organization Continues to Advance its Digital Transformation

Retrieved on: 
Wednesday, August 31, 2022
Partnership, Epilepsy, CEO, Neurological disorder, Social class, Research, Helpline, CDC, TikTok, LLP, Brain, Seizure, Awareness, YouTube, Kutak Rock, Forbes, World, Person, Board, Epilepsy Foundation, Toyota, Sibling, Ad Age, LinkedIn, Live Fast Motorsports, Education, Multimedia, Foundation, Accounting, CFM, NASCAR, Championship Cup Series, Instagram, Board of directors, FDA, Neuro, III, Twitter, Mentorship, Marketing, Child, World Health Organization, Management, Pharmaceutical industry, Gulf states, Facebook

BOWIE, Md., Aug. 31, 2022 /PRNewswire/ -- The Epilepsy Foundation recently selected Jeff Parent as chair of its governing Board of Directors; Mr. Parent succeeds Bradley P. Boyer, Esq., who served as chair for two years. In addition, the Foundation elected nine new board members. Together with the Foundation's staff leadership, the board will advance the organization's efforts to expand its national network of services and support through enhanced digital infrastructure to better connect people with epilepsy to care and resources wherever they are.

Key Points: 
  • In addition, the Foundation elected nine new board members.
  • As chair, I am honored to help the Foundation leverage cutting-edge technology and traditional marketing strategies to reach and engage everyone impacted by the epilepsies."
  • Her desire to volunteer for an organization dedicated to neuro-research and helping impacted families is what led her to the Epilepsy Foundation.
  • With a network of partners throughout the United States, the Epilepsy Foundation is leading the fight to overcome the challenges of living with epilepsy.

Digital rehabilitation platform Neurofenix completes $7 million Series A to transform stroke and brain injury recovery

Retrieved on: 
Tuesday, August 30, 2022
Movement, CEO, Trust, Occupational therapy, Telehealth, View, Arm, Insurance, Entrepreneurship, HTH, Multimedia, Method, Social media, Person-centered therapy, Clinical neuropsychology, Neuro, COVID-19, Brunel University London, Transport, Patient, Pharmaceutical industry, Medical imaging

ATLANTA, Aug. 30, 2022 /PRNewswire/ -- Neurofenix , the neurological rehabilitation platform that uses sensors to improve patient outcomes, has raised $7 million in Series A funding.

Key Points: 
  • ATLANTA, Aug. 30, 2022 /PRNewswire/ -- Neurofenix , the neurological rehabilitation platform that uses sensors to improve patient outcomes, has raised $7 million in Series A funding.
  • This will enable Neurofenix to build out its product line and invest in US expansion, including funding US clinical trials.
  • Neurofenix is the only player in the space providing clinically-validated neuro-rehab combined with patient-centric proprietary technology to enable better patient outcomes.
  • Guillem Singla Buxarrais, CEO and Co-Founder, Neurofenix, said: "Over the last six years, we have been developing our patient-centric sensor-based technology and platform to transform neuro-rehab.

Evolution Optiks Launches Clinical Study of Light Field Tele-Phoropter

Retrieved on: 
Tuesday, August 30, 2022
Research, Technology, Advertising, Telehealth, Dean (education), Solution, Professor, Student, Gold Coast, Medicine, Neuro, Optometry, COVID-19, Eye, LFR, Trial of the century, Patient

CHRIST CHURCH, Barbados, Aug. 30, 2022 /PRNewswire/ -- Evolution Optiks Limited, a privately held company specializing in light field technology, announced today that the first patients were successfully tested in a clinical study evaluating its innovative LFR-260 tele-phoropter against traditional phoropters in visual acuity testing.

Key Points: 
  • CHRIST CHURCH, Barbados, Aug. 30, 2022 /PRNewswire/ -- Evolution Optiks Limited, a privately held company specializing in light field technology, announced today that the first patients were successfully tested in a clinical study evaluating its innovative LFR-260 tele-phoropter against traditional phoropters in visual acuity testing.
  • The prospective, crossover, multi-center, randomized study will include up to 108 patients undergoing a full routine eye examination at three clinical sites in the United States.
  • And as researchers developing advanced ophthalmic technologies, we are pleased to participate in the clinical study of the LFR-260.
  • Founded in 2014, Evolution Optiks Limited is commercializing an extensive and ongoing portfolio of innovation and is on track to revolutionizing how digital information is being consumed.

Optina Diagnostics Earns Frost & Sullivan's 2022 North American Technology Innovation Leadership Award for Leveraging Innovative Eye Imagery and Artificial Intelligence for Chronic Diseases Detection including Alzheimer's

Retrieved on: 
Tuesday, August 30, 2022
Industry analyst, Conditional sentence, Technology, SAN, Achievement, Solution, Best practice, Industry, Amnesia, Physician, Diagnosis, Intelligence, Frost & Sullivan, Alzheimer's disease, Map, Leadership, Neuro, Biomarker, Algorithm, AirAsia, Frost, AI, Government budget balance, Patient, Medical imaging, Medical device

SAN ANTONIO, Aug. 30, 2022 /PRNewswire/ -- Based on its recent analysis of the North American Hyperspectral Retinal Imaging Industry, Frost & Sullivan recognizes Optina Diagnostics with the 2022 Technology Innovation Leadership Award for offering sophisticated artificial intelligence (AI)-powered Retinal Deep Phenotyping™ solutions. Optina Diagnostics' comprehensive technology facilitates early and non-invasive diagnostic tests for chronic diseases including neurodegenerative conditions with its highly differentiated hyperspectral retinal imaging camera, the Optina-4C™, significantly improving standard clinical practices.

Key Points: 
  • Optina Diagnostics' solutions enable specialists and primary care physicians to diagnose chronic diseases including Alzheimer's with reliable and precise retinal scans.
  • SAN ANTONIO, Aug. 30, 2022 /PRNewswire/ -- Based on its recent analysis of the North American Hyperspectral Retinal Imaging Industry, Frost & Sullivan recognizes Optina Diagnostics with the2022 Technology Innovation Leadership Award for offering sophisticated artificial intelligence (AI)-powered Retinal Deep Phenotyping solutions.
  • Optina Diagnostics' comprehensive technology facilitates early and non-invasive diagnostic tests for chronic diseases including neurodegenerative conditions with its highly differentiated hyperspectral retinal imaging camera, the Optina-4C, significantly improving standard clinical practices.
  • Optina Diagnostics is developing its awAIr cerebral amyloid status test to facilitate the reliable and early detection of Alzheimer's disease.

Optina Diagnostics Earns Frost & Sullivan's 2022 North American Technology Innovation Leadership Award for Leveraging Innovative Eye Imagery and Artificial Intelligence for Chronic Diseases Detection including Alzheimer's

Retrieved on: 
Tuesday, August 30, 2022
Industry analyst, Conditional sentence, Technology, SAN, Achievement, Solution, Best practice, Industry, Amnesia, Physician, Diagnosis, Intelligence, Frost & Sullivan, Alzheimer's disease, Map, Leadership, Neuro, Biomarker, Algorithm, AirAsia, Frost, AI, Government budget balance, Patient, Medical imaging, Medical device

SAN ANTONIO, Aug. 30, 2022 /PRNewswire/ -- Based on its recent analysis of the North American Hyperspectral Retinal Imaging Industry, Frost & Sullivan recognizes Optina Diagnostics with the 2022 Technology Innovation Leadership Award for offering sophisticated artificial intelligence (AI)-powered Retinal Deep Phenotyping™ solutions. Optina Diagnostics' comprehensive technology facilitates early and non-invasive diagnostic tests for chronic diseases including neurodegenerative conditions with its highly differentiated hyperspectral retinal imaging camera, the Optina-4C™, significantly improving standard clinical practices.

Key Points: 
  • Optina Diagnostics' solutions enable specialists and primary care physicians to diagnose chronic diseases including Alzheimer's with reliable and precise retinal scans.
  • SAN ANTONIO, Aug. 30, 2022 /PRNewswire/ -- Based on its recent analysis of the North American Hyperspectral Retinal Imaging Industry, Frost & Sullivan recognizes Optina Diagnostics with the2022 Technology Innovation Leadership Award for offering sophisticated artificial intelligence (AI)-powered Retinal Deep Phenotyping solutions.
  • Optina Diagnostics' comprehensive technology facilitates early and non-invasive diagnostic tests for chronic diseases including neurodegenerative conditions with its highly differentiated hyperspectral retinal imaging camera, the Optina-4C, significantly improving standard clinical practices.
  • Optina Diagnostics is developing its awAIr cerebral amyloid status test to facilitate the reliable and early detection of Alzheimer's disease.

BetterLife Lead Drug (BETR-001) Promotes Structural Neural Plasticity with Possible Nootropic Effects Similar to That of LSD Without Hallucinogenic Side Effects

Retrieved on: 
Wednesday, August 24, 2022
COVID-19, Prefrontal cortex, CEO, CSE, Post-traumatic stress disorder, Lists of diseases, Neuron, Hallucination, Disorder, IND, Headache, Experimental Neurology, Anxiety, RATS, Patent, Ketamine, Depression, GLOBE, Neurology, Neuro, Degenerative disease, Growth, LSD, Patient, Pharmaceutical industry

A recent study, published in Experimental Neurology , has provided some new evidence that LSD has nootropic effects which are believed to be driven by neuroplasticity promotion.

Key Points: 
  • A recent study, published in Experimental Neurology , has provided some new evidence that LSD has nootropic effects which are believed to be driven by neuroplasticity promotion.
  • Researchers found that LSD increased neuroplasticity in human brain organoids, increased novelty preference in rats, and improved memory performance in humans.
  • Increased structural plasticity in the brain neurons (mainly prefrontal cortex) has also been linked to the sustained antidepressant effects.
  • These results confirm that our proprietary BETR-001, an LSD analog, retains the anti-depressant and neural plasticity activity of LSD without causing hallucination.

Long COVID-19 study identifies novel blood markers as potential diagnostic and therapeutic targets

Retrieved on: 
Tuesday, August 23, 2022
COVID-19, Lists of diseases, AWY, SomaLogic, Therapy, Brain, Protein, Industry, ANP, Blood, Patent, Miss Colorado USA, GLOBE, Company, Neuro, Invention, Proteomics, Patient, Pharmaceutical industry

The study has elucidated novel blood markers as potential diagnostic and therapeutic targets in the treatment of Long COVID-19 patients.

Key Points: 
  • The study has elucidated novel blood markers as potential diagnostic and therapeutic targets in the treatment of Long COVID-19 patients.
  • This data has been included in recently filed patent applications as potential diagnostic and therapeutic targets for the treatment of Long COVID-19.
  • Certain targets when combined (as few as 5) identified all 48 Neuro Covid-19 patients and the 42 of 44 subjects who were convalescent or healthy controls suggestive of these targets diagnostic potential.
  • Encouragingly, one of the potential therapeutic markers in Long COVID-19 patients identified from this proteomics analysis is also known as having the potential to be significantly modulated by ATL1102 in DMD patients and therefore is suggestive of its therapeutic potential in Long COVID-19.

Long COVID-19 study identifies novel blood markers as potential diagnostic and therapeutic targets

Retrieved on: 
Monday, August 22, 2022
COVID-19, Lists of diseases, AWY, SomaLogic, Therapy, Brain, Protein, Industry, ANP, Blood, Patent, Miss Colorado USA, GLOBE, Company, Neuro, Invention, Proteomics, Patient, Pharmaceutical industry

The study has elucidated novel blood markers as potential diagnostic and therapeutic targets in the treatment of Long COVID-19 patients.

Key Points: 
  • The study has elucidated novel blood markers as potential diagnostic and therapeutic targets in the treatment of Long COVID-19 patients.
  • This data has been included in recently filed patent applications as potential diagnostic and therapeutic targets for the treatment of Long COVID-19.
  • Certain targets when combined (as few as 5) identified all 48 Neuro Covid-19 patients and the 42 of 44 subjects who were convalescent or healthy controls suggestive of these targets diagnostic potential.
  • Encouragingly, one of the potential therapeutic markers in Long COVID-19 patients identified from this proteomics analysis is also known as having the potential to be significantly modulated by ATL1102 in DMD patients and therefore is suggestive of its therapeutic potential in Long COVID-19.

Global Neurostimulation Devices Market to 2030 - Featuring Abbott Laboratories, Advanced Bionics, B. Braun Melsungen and Boston Scientific Among Others - ResearchAndMarkets.com

Retrieved on: 
Friday, August 19, 2022
Medical Devices, Health, Death, Pain management, Patient satisfaction, Chronic pain, Application, Industry, Silicon, American Academy, Lists of diseases, Technology, Growth, Investment, Alzheimer's disease, Calibration, Incidence, American Academy of Neurology, Engineering, Statistics, COVID-19, SCSI Peripheral Device Type, Estimation, CAGR, Neuro, Boston Scientific, Parkinson's disease, USD, Video game, Medical device, Pharmaceutical industry, Risk management

The global neurostimulation devices market held a market value of USD 7,622.7 Million in 2021 and is estimated to reach USD 17,367.0 Million by the year 2030.

Key Points: 
  • The global neurostimulation devices market held a market value of USD 7,622.7 Million in 2021 and is estimated to reach USD 17,367.0 Million by the year 2030.
  • The increasing neurological diseases across the globe, rising clinical trials for neurostimulation devices, investments by companies, are driving factor for the growth of the neurostimulation devices market.
  • Such a factor aids significantly in increasing the growth rate of the neurostimulation devices market
    The global neurostimulation devices market report answers questions such as:
    What is the market size and forecast of the global neurostimulation devices market?
  • What modes and strategic moves are considered favorable for entering the global neurostimulation devices market?

TransMed7, LLC Announces First Clinical Use of Heron Soft Tissue Biopsy Devices for Commercial Launch

Retrieved on: 
Tuesday, August 16, 2022
Biotechnology, Surgery, Medical Devices, Health, Oncology, FDA, Liver, Cardiovascular disease, Cardiovascular and Interventional Radiological Society of Europe, BPH, RSNA, CEO, College of Medicine, Diagnosis, Breast, Technology, Heron, Clinical, Needle, WCU, Regenerative medicine, XPK, LLC, Federal Food, Drug, and Cosmetic Act, Atlantic Film Festival, Patient, Prostate, Lymph, Globe, Skin, Architecture, RO, XP, Radiological Society of North America, Kidney, Histopathology, Phoenix, Arizona, Physician, XPS, Lung, University, McKesson Corporation, Solution, Blood, Neuro, RCU, Biopsy, Medicine, Medical imaging, Medical device

The whole biopsy procedure was finished in less than 5 minutes, which represents a significant cost savings as well.

Key Points: 
  • The whole biopsy procedure was finished in less than 5 minutes, which represents a significant cost savings as well.
  • The Heron platform of soft tissue biopsy devices includes three models of hand-held, ultrasound guided, vacuum assisted, full fluid management, SIMC devices.
  • The Heron XPK and XPS full featured models are designed for manual coring length control and automatic tissue transport.
  • The Heron platform devices will provide the most advanced capabilities for biopsy devices featuring needle sizes from 12 to 18 gauge.